Joshua M Hare MD

Cardiology•Miami, FL

Adult Congenital Heart Disease, Heart Failure & Transplantation

Professor, Medicine, University of Miami Leonard M. Miller School of Medicine

Join to View Full Profile

1400 NW 12th AvenueSuite AMiami, FL 33136
Phone+1 305-243-1900
Fax+1 305-243-9927

Education & Training

Mass General Brigham/Brigham and Women's HospitalFellowship, Cardiovascular Disease, 1991 - 1994
Johns Hopkins UniversityResidency, Internal Medicine, 1988 - 1991
Johns Hopkins University School of MedicineClass of 1988

Certifications & Licensure

FL State Medical License 2007 - 2027
MA State Medical License 1991 - 2026
MD State Medical License 1995 - 2022
American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2008-2014
Top Doctors:South Florida Castle Connolly, 2012
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Elected Member The American Society for Clinical Investigation, 2003
Super Doctor SuperDoctors.com
Fellow (FACC) American College of Cardiology
Join now to see all

Clinical Trials

Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure Start of enrollment: 2003 Mar 01
Completed
Phase 2, Phase 3
Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction Start of enrollment: 2005 Mar 22
Completed
Phase 1
Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) Start of enrollment: 2007 Nov 01
Terminated
Phase 1, Phase 2
The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT) Start of enrollment: 2008 Aug 01
Completed
Phase 1, Phase 2
PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study) Start of enrollment: 2011 May 19
Completed
Phase 1, Phase 2
An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM) Start of enrollment: 2013 Feb 20
Completed
Phase 2
Patients With Intermittent Claudication Injected With ALDH Bright Cells Start of enrollment: 2013 Jun 01
Completed
Phase 2
The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study) Start of enrollment: 2014 Feb 13
Completed
Phase 2
Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER) Start of enrollment: 2013 Nov 13
Terminated
Phase 1
AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery Start of enrollment: 2014 Mar 03
Completed
Phase 1, Phase 2
The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial. Start of enrollment: 2025 Mar 01
Withdrawn
Phase 1, Phase 2
Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression Start of enrollment: 2017 Oct 31
Terminated
Phase 1
Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis Start of enrollment: 2020 Dec 01
Withdrawn
Phase 1
Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression. Start of enrollment: 2018 Apr 12
Terminated
Phase 1, Phase 2
A Comparative Study of Subjects Past Their Final Follow-ON Visit Start of enrollment: 2016 Jun 23
Completed
Allogeneic Human Mesenchymal Stem Cell Infusion Vs Placebo in Alcohol Use Disorder and Major Depression. Start of enrollment: 2018 Mar 18
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
The CHILD Trial: Hypoplastic Left Heart Syndrome Study. Start of enrollment: 2019 Oct 16
COMPLETED
PHASE1
Allogeneic Human Mesenchymal Stem Cell Injection in PAtieNts With FaceTogenic Back Pain Start of enrollment: 2020 Dec 01
Withdrawn
Phase 1, Phase 2
Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS) Start of enrollment: 2018 Feb 21
Active, not recruiting
Phase 1, Phase 2
Administration of Allogeneic-MSC in Patients with Non-Ischemic Dilated Cardiomyopathy Start of enrollment: 2021 May 07
RECRUITING
PHASE2
Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19 Start of enrollment: 2022 Oct 01
Withdrawn
Phase 1
Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD) Start of enrollment: 2021 Aug 16
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy Start of enrollment: 2024 Mar 04
RECRUITING
PHASE2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.
Brian G Rash, Kevin N Ramdas, Nataliya Agafonova, Eric Naioti, Lisa McClain-Moss
Nature Medicine. 2025-03-10
Publisher Correction: Growth hormone-releasing hormone and its analogues in health and disease.
Riccarda Granata, Sheila Leone, Xianyang Zhang, Iacopo Gesmundo, Charlotte Steenblock
Nature Reviews. Endocrinology. 2025-03-01
Author Correction: Growth hormone-releasing hormone and its analogues in health and disease.
Riccarda Granata, Sheila Leone, Xianyang Zhang, Iacopo Gesmundo, Charlotte Steenblock
Nature Reviews. Endocrinology. 2025-03-01

Journal Articles

Alterations of Tumor Microenvironment by Nitric Oxide Impedes Castration-Resistant Prostate Cancer Growth
Ranjith Ramasamy, Kush Panara, Himanshu Arora, Joshua M Hare, Proceedings of the National Academy of Sciences
Growth Hormone-Releasing Hormone Attenuates Cardiac Hypertrophy and Improves Heart Function in Pressure Overload-Induced Heart Failure
Joshua Hare, MD, Proceedings of the National Academy of Sciences

Press Mentions

Cell Therapy Shows Potential in Multiple Age-Related DiseasesJuly 18th, 2024
‘Miami Valves’ International Conference Showcases Advances in Treating Cardiovascular DiseaseMarch 3rd, 2023
Heart Disease Study Shows Hope for Stem Cell TreatmentFebruary 27th, 2023
Join now to see all

Grant Support

Full-scale GMP Production for a Pre-Clinical Systemic Delivered Mesenchymal Stem Cells Derived Extracellular Vesicles For Cardiovascular DiseaseUNIVERSITY OF MIAMI SCHOOL OF MEDICINE2023–2025
1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical TrialLURIE CHILDREN'S HOSPITAL OF CHICAGO2020–2025
Cell Based Therapy For Non-Ischemic Dilated CardiomyopathyNational Heart, Lung, And Blood Institute2012
Cardioprotective Effect Of Growth Hormone Releasing HormoneNational Heart, Lung, And Blood Institute2011–2012
Nitroso/Redox Balance In Myocardial InfarctionNational Heart, Lung, And Blood Institute2009–2012
Stem Cells For Dilated CardiomyopathyNational Heart, Lung, And Blood Institute2011
Autologous Adult Myocardial Cardioblasts To Treat Ischemic Heart FailureNational Heart, Lung, And Blood Institute2010–2011
Cellular Cardiomyoplasty For Chronic Heart FailureNational Heart, Lung, And Blood Institute2007–2011
Mesenchymal Stem Cell CardiomyoplastyNational Heart, Lung, And Blood Institute2007–2009
Oxidative Stress In Heart FAILURE: MechanismsNational Heart, Lung, And Blood Institute2007–2008
Aging Impairs Stem-Cell Mediated Myocardial RepairNational Institute On Aging2006–2008
Safety Of Mesenchymal Stem CellsNational Center For Research Resources2006–2007
Mesenchymal Stem Cell CardiomyoplastyNational Heart, Lung, And Blood Institute2005–2006
Aging Impairs Stem-Cell Mediated Myocardial RepairNational Institute On Aging2004–2006
Oxidative Stress In Heart FAILURE: MechanismsNational Heart, Lung, And Blood Institute2000–2006
Core A- Administrative CoreNational Heart, Lung, And Blood Institute2005
Cellular Cardiomyoplasty For Acute And Chronic IschemicNational Heart, Lung, And Blood Institute2005
Mesenchymal Stem Cells And Ventricular RemodelingNational Heart, Lung, And Blood Institute2002–2004
Nitric Oxide, Cardiac Contractility, And Heart FailureNational Heart, Lung, And Blood Institute1995–1999
Nitric Oxide, Cardiac Contractility, And Heart FailureNational Heart, Lung, And Blood Institute1995